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Abstract
Liposomal delivery of Remdesivir for localized and targeted treatment of COVID-19
By
Anupama Melam
Master of Science in Biomedical Engineering
Washington University in St. Louis, 2021
Research Advisor: Professor Kareem Azab

COVID-19 is a serious, and in many cases lethal, disease that is caused by infection of the upper
respiratory tract by the novel betacoronavirus, SARS-Cov-2 virus. This disease has a very high
mortality rate and has affected the world in a global pandemic. SARS-Cov-2 binds to the ACE2
receptor via the receptor-binding domain (RBD) in the S protein. After this, the virus fuses with
the cell membrane by the formation of a six-helix bundle. Thus, the S protein plays a major role
in ensuring that the virus attaches to the ACE2 receptor and enables the viral fusion, entry and
transmission. The ACE2 receptor is essentially the main point of entry for the virus. Some
research efforts have been focused on drugs that can be used for viral-entry inhibition by
targeting human ACE2 receptors. Remdesivir, an antiviral, is a nucleoside RNA polymerase
inhibitor which causes premature termination of viral transcription. Although it is not FDAapproved, it is the current standard of care as some studies have indicated that Remdesivir use
leads to reduced mortality. However, the possible side effects observed are increased levels of
liver transaminase, hypersensitivity, anaphylactic reaction and potential renal failure. The goal of
this study is to improve the therapeutic effects and reduce the side effects by the localized
delivery of Remdesivir using liposomes that target ACE2 receptors in the body.
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Chapter 1: Introduction
Coronaviruses have been around the world for a while and in most cases cause mild to
moderate cold symptoms in patients that are infected. However, some viruses of this family have
caused widespread disease. The 2003 outbreak of Severe Acute Respiratory Syndrome36 (SARS)
and the Middle East Respiratory Syndrome30 (MERS) outbreak, first identified in Saudi Arabia
in 2012, are two viral outbreaks that were caused by coronaviruses. In 2019, patients in Wuhan,
China were infected by another new type of Coronavirus, SARS-Cov-2, which has plagued the
world with Coronavirus Disease 19 (COVID-19) and lead to the Global pandemic of 2019-2020.
This chapter gives a brief introduction to coronaviruses and the SARS-Cov-2 virus.
Coronaviruses
Coronaviruses are a family of RNA viruses called Coronaviridae8 that cause mild to
moderate infection in the upper-respiratory tract of the body leading to diseases like the common
cold. However, three new viruses have impacted the world greatly over the past 20 years by
causing widespread breakouts of diseases such as SARS, MERS, and COVID-19.
The Coronaviridae family has four genera of which two (alphacoronavirus and
betacoronavirus) are known to infect human beings31. The viruses within this family have a ring
of spikes on the outside which resemble a crown. This has earned them the name coronaviruses
(“corona” means crown).
Presently, the mode of transmission for these viruses is through animals – SARS was
transmitted from civet cats, MERS from camels and COVID-19 from bats. Once in humans,
these viruses are transmitted from human to human via coughing, sneezing, touching hands and
close personal contact31.

2
SARS-Cov-2 virus
COVID-19 is a serious, and in many cases lethal, disease that is caused by infection of
the upper respiratory tract by the novel betacoronavirus, SARS-Cov-2 virus. This disease has led
to almost 270,000 deaths in the United States alone14 and has affected the daily lives of
everybody in the world with the pandemic.
SARS-Cov-2 like other coronaviruses is transmitted between people through particles
that are aerosolized when an infected person coughs or sneezes and is transmitted through touch
and close contact within distances < 2m31. It has been proposed that the virus may also be
transmitted from contaminated surfaces since laboratory studies have indicated that the virus can
live on plastics, cardboard and stainless steel for days39.

Figure 1: Structure of the SARS-Cov-2 virus18
This figure shows the 4 main structural proteins of the virus – the N, S, M and E proteins. The
spikes on the outside of the virus have earned it the name Coronavirus, corona meaning crown.
This figure is adapted from a publication by Florindo et al18.
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SARS-Cov-2 virus is an “enveloped, non-segmented, positive sense RNA virus” that has
a diameter of 65–125 nm, containing single strands of RNA and has spikes on the outside that
resemble a crown. The SARS-Cov-2 virus has 4 main structural proteins namely, spike (S)
glycoprotein, envelope (E) glycoprotein, membrane (M) glycoprotein, and nucleocapsid (N)22.
Like SARS-Cov-1, the virus that caused the SARS outbreak, SARS-Cov-2 binds to Angiotensin
Converting Enzyme 2 (ACE2) receptors in the body. The virus first binds to the ACE2 receptor
via the receptor-binding domain (RBD) in the S protein. After this the virus fuses with the cell
membrane by the formation of a six-helix bundle22. Thus, the S protein plays a major role in
ensuring that the virus attaches to the ACE2 receptor and enables the viral fusion, entry and
transmission. Many research efforts, especially in the development of monoclonal antibodybased treatments, are focused on studying the structure of this S protein in order to develop
treatment that target this S protein and its subunits.
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Chapter 2: COVID-19 disease
The outbreak of COVID-19 began in Wuhan, China in late 2019 and by February 2020
China had reported 75000 cases and 2000 deaths28. Since then, the disease spread rapidly
resulting in nearly 63.5 million cases and 1.5 million deaths worldwide14 as of December 1,
2020. These statistics are expected to be an underestimate of the actual numbers of cases and
deaths due to the limited access to testing leading to unreported cases and delayed testing of
infected patients. Presently, the only actions people have been taking to prevent the spread of the
virus are isolation and quarantine.
COVID-19 has impacted people irrespective of age. There are, however, some
populations that are at higher risk than others. People that are immunocompromised, have other
risk factors such as diabetes and hypertension, and those that are of advanced age are considered
to be most “at risk”. Recent studies suggest that people that have blood type A are at a higher
risk compared to other non-A groups while with people with blood type O have the lowest risk46.
The disease has also impacted people’s daily lives outside of the physiological impact to
their physical health. People’s mental health has taken a toll with many health care workers and
families suffering from Post-Traumatic Stress Disorder (PTSD) due to the quarantines and
isolation. The lockdown amidst the global pandemic has impacted people’s livelihood – small
businesses are shutting down; many people are suffering from lay-offs and furloughs and the
economy saw a recession in early 2020.
This section describes what the disease looks like in patients – the symptoms and the
pathophysiology of the infection and how the disease progresses through the patient’s body.
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Symptoms
In most patients, signs and symptoms appeared 2-14 days after exposure to the virus. The
virus has an incubation period of about 14 days after which symptom onset begins. Some of the
most common symptoms13 are:
•

Fever

•

Cough

•

Tiredness

•

Loss of the sense of smell usually accompanied by the loss of sense of taste

The report published by the Chinese Center for Disease Control (Chinese CDC) in the
Journal of the American Medicine Association (JAMA) in February 2020 divided the clinical
manifestations of the disease by the severity in symptomatic affected patients:
•

Mild disease: no to mild pneumonia (81% of cases)

•

Severe disease: dyspnea, respiratory frequency ≥30/min, blood oxygen saturation
≤ 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio (i.e.,
P/F ratio) < 300, and/or lung infiltrates > 50% within 24-48 hours (14% of cases)

•

Critical disease: respiratory failure, septic shock, multiple organ failure (5% of
cases)

These statistics were reported based on data collected about the 72,314 (confirmed,
suspected, diagnosed and asymptomatic) cases reported by the Chinese CDC in the paper42.
Other symptoms that have been identified include weakness, respiratory distress malaise and
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muscle pain . The length of infection varies from person to person – some people recover within
weeks of symptom onset while others take much longer (sometimes even months) to recover.
Although many people, especially in the United States, are required to perform regular
health checks to identify a fever or notice any other symptoms, the issue is complicated by the
fact that many people that have COVID-19 are asymptomatic. People that have been exposed to
the virus may be asymptomatic and can also infect other people. Therefore, the lack of symptoms
gives people a false sense of security.
The only way COVID-19 is clinically diagnosed is through a combination of clinical
symptoms, testing for presence of viral RNA via RT-PCR through nasal swabs, chest x-ray or
CT scans and quantifying antibodies produced by the body via a blood sample2. There are 2 main
types of tests that are being administered in patients – the PCR tests in which a nasal swab is
taken from a person to detect for viral RNA and the blood serology test which detects the
antibodies that the patient’s body produced in response to the viral infection. While there are
severe limitations to testing such as - false positives and lack of enough tests for people around
the world, it is currently the best method to check for infection. When used in conjunction with
other methods like the chest x-ray the tests have been very helpful for identifying infected
patients and to start contact tracing so other people that may have been exposed to the virus may
be informed.
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Pathophysiology
Since the outbreak of COVID-19 many researchers have been trying to identify the
pathophysiology of the disease and learn about the virus transmission in the hope to find ways to
stop the spread. Early in the outbreak, positive cases were observed mostly among older
populations – specifically in older men with comorbidities32. As the disease has spread and more
people have been affected more has been learned about the disease and its pathophysiology.

Infection Route
SARS-Cov-2, the virus that causes COVID-19, enters the body through aerosolized
droplets often released into the air by other infected patients when they cough, speak, sneeze,
touch surfaces, through physical contact etc. Once the virus has entered the body it goes through
5 main steps –
•

Attachment – virus binds to the receptor

•

Penetration – virus enters the cells (either through membrane fusion or through
endocytosis)

•

Biosynthesis – viral proteins are made in the host using the viral RNA

•

Maturation – new viral particles are made using the viral proteins

•

Release – newly made viral particles are then released back and the whole process
repeats45

The Spike (S) protein plays a major role in the virus attaching and fusing with the host
cells. The S protein has two main subunit – the S1 subunit, which is responsible for the virus
binding with the host cells’ receptors (attachment) and the S2 subunit which is responsible for the
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fusion of the virus with the host cells’ membranes (penetration). The S1 subunit of SARS-Cov-2
binds to the Angiotensin Converting Enzyme 2 (ACE2) receptor45. The ACE2 receptor is highly
expressed in pulmonary epithelial cells26. After binding with the ACE2 receptor, the S protein
goes through a 2-step protease cleavage – the first cleavage to prime the S1/S2 cleavage site by
the Transmembrane serine protease 2 (TMPRSS2)11 and the second activates a position adjacent
to the fusion in the S2 subunit.
Once the fusion is complete, the virus enters the pulmonary alveolar epithelial cells
where the viral RNA is released. The virus then begins replication based on the viral RNA
template. Then transcription is completed via RNA polymerases and the newly formed replicate
can be used to produce new proteins in the cell cytoplasm through translation. This process is
called biosynthesis.
The virus’ N protein then binds the newly made RNA material and the M protein enables
their integration into the host cell’s endoplasmic reticulum (ER). The N proteins are then
enclosed in the ER and transported to the lumen from where the Golgi transports it to the cell
membrane. During this time the newly made viral particles made from the viral proteins are
undergoing maturation.
After the viral particles reach the cell membrane, they then are taken outside the cell via
exocytosis and released so that they can invade new epithelial cells and continue proliferation.
Once the viral particles have been released, they can also be transmitted outside the patient’s
body through aerosolized droplets to infect the next person.
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Figure 2: Infection route for SARS-Cov-245

Disease Progression
According to the Treatment guidelines published by the NIH and updated with the latest
findings, COVID-19 disease progression is thought to have two main stages – the initial stage
post infection where the disease primarily involves replication of the SARS-Cov-2 viral particles
and the later stage where the disease is driven by inflammation in response to the virus particles
which leading to tissue damage1.
The SARS-Cov-2 viral particles are spread primarily through respiratory droplets or by
surface contamination. Namely, face-to-face exposure with an individual with COVID-19 puts
one at higher risk of being infected, especially if the infected individual coughs, sneezes, or talks
in a way that spreads saliva droplets. The average time from exposure of the virus to the first
symptoms averages around 5 days, with 97.5% of people who do develop symptoms develop
them within 11.5 days from exposure. The most common symptoms include fever, shortness of
breath, and dry cough. Patients developing symptoms may also develop weakness, fatigue,
nausea, vomiting, diarrhea, changes to taste and smell.
However, severe complications can occur affecting primarily the heart and lungs in
addition to the liver, kidney and coagulation system. COVID-19 can also lead to myocarditis,
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cardiomyopathy, ventricular arrythmias and hemodynamic instability . About 17-35% of
patients suffering from COVID-19 are treated in ICUs most often due to Acute Respiratory
Distress Syndrome (ARDS), pneumonia or hypoxemic respiratory failure. Of these patients in
the ICU, anywhere from depending on the severity of the disease, the extent of disease
progression and the combination of risk factors.
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Chapter 3: Treatments for COVID-19
The magical cure for COVID-19 has been a priority for research efforts across the globe
since the outbreak in Wuhan, China. However, there are no drugs approved by the Food and
Drug Administration (FDA) for the treatment. The SARS-Cov-2 viral genome undergoes high
error rates and recombination (homologous and non-homologous). This is because of the virus’
short replication time and high viral yields2. This section summarizes some of advancements that
have been made towards the treatment of COVID-19 including prophylactic measures (to
prevent infection) and post exposure treatments.

Vaccines (Pre-exposure)
Many scientists and pharmaceutical companies are working on finding a vaccine for the
disease so that healthy people can be protected from getting infected when exposed to the
vaccine. This way people would not have to suffer any of the potentially severe symptoms and
the world can go back to functioning per usual back to what is now considered “pre-COVID-19”.
There are 3 main types of vaccines that are currently in varying stages clinical trials. These types
are Adenovirus-based vaccines, Vesicular Stomatitis Virus-based vaccines, mRNA vaccines.

Figure 3: Summary of the different types of vaccines
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Adenovirus-based vaccines
Adenovirus-based vaccines work by inserting a segment of the SARS-Cov-2 viral
genome into a rare virus, that does not cause any significant harm, so it can produce SARS-Cov2 protein. This rare virus loaded with the SARS-Cov-2 genome is then injected into the body to
trigger an immunogenic response in the body. The biggest challenge with this process is that the
transport virus (adenovirus) must be rare to humans, i.e., most people have not been exposed to
it, in order to prevent the body from recognizing it as a threat and destroying it before the virus
can infect other cells with the SARS-Cov-2 proteins. An alternative to using rare human
adenoviruses is to use monkey adenoviruses but these have to be capable of infecting humans
(which is unlikely to be naturally occurring or they would have infected humans by now).
Johnson & Johnson (J&J) and Janssen Pharmaceuticals are currently working on a
potential vaccine of this type called JNJ-78436735 (also called Ad26.COV2-S). They are in their
second round phase III clinical trials. Their vaccine uses the replication-defective adenovirus
type 2623. AstraZeneca in collaboration with the University of Oxford has also developed a
potential vaccine called AZD1222 (also known as ChAdOx1 nCoV-19). They are using a simian
adenovirus. They are doing their phase 3 of clinical trials10.

Vesicular Stomatitis Virus-based Vaccines
Vesicular stomatitis virus (VSV) can be used as a delivery vehicle to transport SARSCov-2 viral genes that trigger antigen-production in human cells. VSVs are used as vaccine
vectors because they induce a strong T cell immune response in the body after just a single dose.
The cytopathic nature of VSV makes it a strong candidate for use in the production of vaccines.
VSV infections in humans are rare (it primarily affect cattle and livestock) and once infected the
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patient experiences mild influenza-like symptoms. Additionally, the genetic flexibility of VSV
enables the production of rVSVs that express high levels of foreign viral proteins – in this case
SARS-Cov-2 proteins20.
Merck is developing a potential oral antiviral vaccine called MK-4482. This is a vaccine
based on the rVSV vector. This vector has been successful in combatting Ebola. Currently they
are in Phase II/III of clinical trials for this vaccine29.
mRNA Vaccines
mRNA vaccine is a new type of vaccine that works, not by inserting live or weakened
viruses like the previous two types, but by inducing cell production of the protein or a piece of
the protein that triggers an immune response12. mRNA in itself is a relatively safe vector since it
only carried information for a short while and does not affect the body’s genome. mRNA
vaccines produce a balanced immune in the body and the combination of the desired
immunogenic response induced in the body and the minimal side effects makes mRNA vaccines
are very attractive option6. The only major limitation with the production of mRNA vaccines is
that since viral vectors are not used the mRNA needs to be enclosed in a complex lipid delivery
system to prevent it from degrading either outside the cell or in the cytoplasm33.
Currently, the two vaccines with the most potential and the highest efficacy (94.5%) are
mRNA vaccines. Moderna has developed mRNA-1273, a potential vaccine made by
encapsulating the mRNA is a lipid nanoparticle. This mRNA encodes for a “full-length,
prefusion stabilized spike (S) protein of SARS-CoV-2” triggering the production of antigens that
target this S protein. Presently, this vaccine has completed Phase III of testing5. Moderna is
awaiting FDA approval for use in the United States and Europe.
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Another major vaccine candidate is BNT162b2 developed by BioNTech, Fosun Pharma
and Pfizer. Like the vaccine candidate developed by Moderna, this is also a lipid nanoparticleencapsulated mRNA vaccine. This vaccine has also completed Phase III trials and has filed for
an Emergency Use Authorization (EUA) with the FDA. This vaccine has been approved and is
currently being deployed particularly to high-risk populations like people over the age do 65 and
frontline healthcare workers. It has already been authorized for use in the UK on December 2,
202034.

15
Drugs (Post exposure)
Drug treatment of patients with COVID-19 depends on the stage and the severity of the
disease and on potential risk factors and co-morbidities that the patient has. Earlier in the disease
progression antivirals and antibody-based treatments are very effective. However later stages in
the disease progression are often marked by hyperinflammatory responses and coagulopathies. In
these stages anti-inflammatory drugs and anticoagulants are more effective than antivirals4.
While there are no FDA approved drugs to treat COVID-19, a large variety of drugs have been
tried both in research labs and in hospitals. Since COVID-19 is caused by a coronavirus and the
spread was so rapid, many drugs that worked in the past have been repurposed for the treatment
of COVID-19. The Infectious Diseases Society of America (IDSA) published their guidelines on
the use of various treatments for COVID-19. These guidelines are regularly updated with latest
findings from ongoing studies. This section summarizes some of the most popular treatment
types, outlined by IDSA, that have been tested and the benefits and challenges with each type.

Repurposed treatments
Early on the search for the treatment of COVID-19, Chloroquine (CQ) and its less toxic
counterpart Hydroxychloroquine (HCQ) were tested to check their efficacy against SARS-Cov2. Both CQ and HCQ are 4-aminoquinoline drugs that were previously used in the treatment of
Malaria. HCQ has an extra hydroxyl group (hence the name) which leads fewer severely adverse
effects with use overtime. These drugs have been tested in vitro and these studies have shown
that these drugs have some activity against SARS-Cov-224. A study that aimed to optimize the
dose of HCQ and CQ by testing pharmacological activity in vitro found that HCQ is more potent
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that CQ in vitro . One non-randomized study reported a reduction in mortality in patients
suffering from COVID-19 when treated with HCQ44.
However, while HCQ was considered a potential drug candidate for the treatment of
COVID-19 it is no longer under consideration due to side effects such as – longer time until
discharge, risk of QT prolongation, arrythmias and hemolysis among others. Furthermore, there
were concerns about the validity of the studies because there was no measure taken to control for
critical cofounders of disease severity, to factor steroid uses given their additional benefits
(steroid use thus is a confound that should have been removed to understand the effect of HCQ
alone) etc.

Antibody treatments
The second stage of COVID-19 involves a hyperinflammatory response often
characterized by a “cytokine storm”7. Descriptions of infected patients and their
immunopathology indicated that those with higher levels of IL-6 and hyperinflammatory
response had more severe disease symptoms3. Tocilizumab, a monoclonal antibody, is being
considered a potential drug candidate due to its anti-IL-6-receptor blocking property thereby
reducing hyperinflammatory response.
While there was some evidence of lower clinical deterioration in one study, the results
were of low certainty due to bias and imprecision. To make things worse, Tocilizumab use for
treatment of COVID-19 in patients led to case reports of bowel perforations. Since the drug did
not provide any significant benefit when compared to outcomes of untreated patients and there
was significant risk to its use, there is a conditional recommendation against the use of
Tocilizumab.
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Corticosteroid treatments
In order to reduce the hyperinflammatory response observed in the later stages of
COVID-19 investigations began to identify potential immunomodulatory approaches, involving
the use of steroids, to treat COVID-19. The hyper-inflammatory response is potentially what
causes Acute Respiratory Distress Syndrome (ARDS) in some patients1. Patients with ARDS
required prolonged use of ventilators. Corticosteroids are known to alleviate non-viral ARDS25.
Hence, they were considered as a potential treatment for the later stages of COVID-19.
Dexamethasone is most effective in critically ill patients – odds of mortality were 34%
less in patients treated with glucocorticoids vs those that were not1. Also, patients that received
Dexamethasone were more likely to be discharged from the hospital. In patients with severe
illness, odds of mortality were 17% in patients treated with glucocorticoids vs those that were
not. In patients that were not suffering from severe or critical illness, Dexamethasone did not
produce any significant benefit or harm. It is therefore advised to be used only in patients with
severe or critical illness. If Dexamethasone is unavailable, other glucocorticoids are to be used.

Antivirals
Remdesivir (aka Veklury, GS-5734) is one the most important anti-viral drugs that is
being considered for COVID-19 treatment. Remdesivir, while currently not fully authorized for a
treatment, it is currently approved by the FDA under Emergency Use Authorization (EUA) and
is the current standard of care, especially for patients early on in the disease progression.
Remdesivir is a nucleoside RNA polymerase inhibitor which causes premature
termination of viral transcription40. In vitro studies have shown that Remdesivir is effective in
preventing replication of SARS-Cov-1 and MERS-Cov viruses in Human Airway Epithelial
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(HAE) cells . An in vivo study in Rhesus Macaques infected with SARS-Cov-2 showed that the
animals had improved pulmonary lesions, reduced viral load titers in bronchoalveolar lavage
12hours post treatment and reduced viral load in lungs after 7 days41.
When used in patients some studies have shown decrease in mortality and improved
clinical outcomes after being treated with Remdesivir1. However, some patients reported side
effects such as increased levels of liver transaminase, hypersensitivity, anaphylactic reaction and
potential renal failure38.
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Chapter 4: Hypothesis and Research Objective
Remdesivir is the current standard of care for patients suffering from COVID-19 per the
FDA. However, the less-than-ideal efficacy and the risk of possible side effects from increased
liver transaminase levels to potential renal failure has rendered the drug subpar.
The goal of this study is to improve the therapeutic effects and reduce the side effects by
the localized delivery of Remdesivir using liposomes that target ACE2 receptors in the body.

Figure 4: Schematic representation of the liposome and its route
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Chapter 5: Methods and Results
About liposomes
Liposomes are small spherical particles that typically have one or more hydrophobic
layers surrounding a hydrophilic core. This hydrophobic shell is typically made up of a
phospholipid bilayer. Liposomes have become very important and widely used vehicles for drug
transport. This popularity is due to multiple factors including how well drugs can be
encapsulated inside these nanoparticles, the ease of preparation and the standardization of size,
and most importantly the dual regions. The dual regions are the key benefit since drugs can be
loaded in either (or both) of the regions based on the hydrophilicity of the drug. Further,
antibodies and proteins can be added to the surface of the liposome particles adding more
functionality to the particles.

Figure 5: Schematic representation of a liposome35
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Preparation of liposomes
Liposomes were prepared using the thin layer evaporation method16. The hydrophobic
layer is made up of DPPC, Cholesterol and PEG-succinyl. Since Remdesivir dissolves in
hydrophobic solutions (soluble in DMSO, insoluble in water and ethanol), it was added along
with the lipids. The lipids and Remdesivir were dissolved in 1 ml Chloroform. 10ul of Ethanol
was added to ensure the lipid film was unilamellar. This solution was evaporated through a
rotary evaporator (Heidolph, Schwabach, Germany) to form a thin lipid film. The lipid film was
hydrated with PBS (to produce liposomes) and then extruded to ensure liposomes were uniform
and of a specific size. The extruded set by Avanti Polar Lipids was used for this and the
liposomes were extruded though 200nm and 100nm filters. The size, polydispersity index (PDI)
and the zeta-potential of the liposomes were determined using the Zetasizer Nano ZS which
measures these parameters using Dynamic Light Scattering (DLS).

Figure 6: Steps involved in the preparation of liposomes17

To make targeted liposomes with anti-ACE2 receptors on the surface of the liposomes,
carbodiimide chemistry. Appropriate volumes of EDC and NHS with original concentrations of
200uM (in Milli-Qâ water) were added and the liposomes were incubated at room temperature
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for 15 minutes with gentle stirring. The solution of liposomes with EDC and NHS was then split
into two groups – one group of liposomes with anti-ACE2 receptors and one group of nontargeted liposomes. To the first group anti-ACE2 receptors were added. Both groups of solutions
were placed in dark bottles in 4°C in a light-protected environment and incubated overnight with
gentle stirring. Unbound anti-ACE2 receptors were filtered out using ultracentrifuge to remove
the supernatant solution.
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Characterization of liposomes

Figure 7: Zetasizer Nano ZS by Malvern Panalytical used for DLS analysis

Dynamic Light Scattering (DLS) analyzers are machines that measure the size of really
small particles that are in solution. These analyzers detect the particle sizes based on the
fluctuations in the scattered light created by the Brownian motion of the particles. This is why it
is critical to have the particles in solution so that they exhibit Brownian motion. DLS analyzers
are able to characterize liposomes based on a number of parameters. For this experiment the
most important were size, PDI and zeta potential.

Table 1: Characteristics of the liposomes identified by the DLS analyzer
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The DLS analysis showed that the mean size of the liposomes was 117nm with a standard
deviation of 1.15 which makes sense since the liposomes were extruded through 100nm
membrane filter. According to a review by Danaei et al while there is no ideal size for the
treatment of systemic disease determined yet, in order to maximize protein interaction,
transepithelial transport and to delay lung clearance the particle size must be less than 150nm15.
With the particle size at 117nm, the liposomes are ideal for delivery of Remdesivir specifically to
the lungs.
The Polydispersity Index (PDI) of the liposomes were determined to be 0.09 (with a
standard deviation of 0.03). PDI describes the particle size dispersion. So, a smaller PDI means
all the particles are the same size while a larger PDI means that there is a lot of variability. For
drug delivery through nanoparticles and liposomes, a PDI £ 0.3 is considered acceptable15. Based
on these guidelines a PDI of 0.09 is really good and indicates that the liposomes are uniform in
size around 117nm.
The average zeta potential of the liposomes was -42.03mV. The zeta potential is a
measure of the surface charge on the particles and indicates how stable the nanosuspensions are.
Zeta potentials that are greater than +30mV and less than -30mV indicate good physical particle
stability4. This is because the magnitude of the surface charge on the particles is sufficiently
large to repel neighboring particles minimizing agglomeration. Thus, the zeta potential of the
liposomes prepared (which is < -30mV) indicates that the liposome particles are very stable in
solution and do not aggregate.
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Testing liposome receptor binding
In order to test if the anti-ACE2 receptors on the surface of the liposomes were indeed
successful at binding to the ACE2 receptors on the epithelial cells liposomes with no drug were
coated with anti-ACE2 receptors and recombinant ACE2 protein. These liposomes were
prepared in the exact same way as before – however no Remdesivir was added with the lipids
and DiD was added to the lipids (before dissolving in Chloroform) to make fluorescent
liposomes. When conjugating with EDC and NHS, the solution of liposomes with EDC and NHS
were split into three dark brown bottles – one group with anti-ACE2 receptors, and the other
group with no targeting.
A 96-well plate was prepared with 2 different solutions, 1 solution in each row –BSA
(1mg/ml) and recombinant ACE2 protein (5.7ug/ml). To coat the wells with each solution, 35ul
was added to each well, just enough to cover the bottom of the well, the plate was sealed and
places in 4°C for 48 hours. The plate was then rinsed with PBS and the liposomes were added
(down the column). The plate was covered with aluminum foil and placed at room temperature
for 1hour. The fluorescence was measured using a SpectraMax i3 Spectrophotometer.

Figure 8: 96-well plate arrangement of the solutions and the liposomes
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This experiment was repeated 3 times for most accurate results since ensuring that the
binding did indeed take place was the most important step. In the first trial, the initial
concentration of liposomes of 28.57ug/ul was used. 50ul of liposomes were pipetted into each
well. After allowing the liposomes to bind to the solutions, the fluorescence was measured first
with liposomes in the wells, then after they were aspirated and after each rinse with PBS. The
fluorescent dye used to color the liposomes was DiD which has an excitation wavelength of
648nm and an emission wavelength of 675nm. The fluorescence was then compared across
rinses and plotted on a graph. However, in this trial, some of the data from the early PBS washes
was lost and the only data recovered was from the fourth wash with PBS. The results were not
accurate, and a second trial of the experiment was carried out.
In Trial 2 some of the mistakes from Trial 1 were fixed. The first change was the use of a
black 96-well plate. This was used in order to reduce internal reflections when using the
fluorescence plate reader. The black plate was also covered by an aluminum when the solutions
were coating the bottom for 48hours. The second change was that the liposomes were diluted
approximately 1:3.5. The new concentration of liposomes used was 8.729ug/ul (compared to the
original concentration of 28.57ug/ul). Another big change made was that after the 48hours of
incubating the solutions on the wells, the 96 well plate was rinsed with BSA to minimize nonspecific binding. The fluorescence data was collected only after PBS was added between washes,
not after aspirating it. The results from the fluorescence plate reader were then plotted as shown
in Figure 1.
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Figure 9. Plot of relative fluorescence for Trial 2 of the affinity binding experiment
This figure indicates that the targeted liposomes with the anti-ACE2 antibody (Red) binds almost
2x more to the recombinant ACE2 protein solution than the non-targeted liposomes (Blue). The
lower non-specific binding to BSA indicates that the liposomes with anti-ACE2 antibodies bind
specifically to the recombinant ACE2 protein.
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The results from Trial 2 looked very promising. BSA was used in order to compare the
non-specific binding of the liposomes with the specific binding of liposomes. Recombinant
ACE2 protein was used as the binding solution so it can mimic the ACE2 receptors that are
present in the human body. As expected, the anti-ACE2 targeted liposomes had almost 2x more
specific binding than the non-targeted liposomes indicating that the liposomes with the antiACE2 antibody was able to successfully bind specifically. In order to fine-tune the results, one
more trial was conducted to show repeatability and to improve accuracy.
In the Trial 2, the data indicated that the fluorescence for each well was too high. So, for
Trial 3, the liposomes were diluted 1:10 for a final concentration of 0.8729ug/ul. The plates were
placed in the cold room for 24hours and similar to Trial 2, the fluorescence was only read after
the PBS was added and not after it was aspirated. This data was again collected and plotted in
Figure 2.
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Trial 3 of Affinity Binding Experiment
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Figure 10. Plot of relative fluorescence for Trial 3 of the affinity binding experiment
This figure also shows that the targeted liposomes with the anti-ACE2 antibody (Red) binds >2x
more to the recombinant ACE2 protein solution than the non-targeted liposomes (Blue). The
lower non-specific binding to BSA indicates that the liposomes with anti-ACE2 antibodies bind
specifically to the recombinant ACE2 protein. The fine tuning of the experiment made the
difference between specific and non-specific binding clearer.
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The results from Trial 3 proved that the liposomes with anti-ACE2 antibody were indeed
capable of targeting and binding specifically to the recombinant ACE2 protein. Since the
recombinant ACE2 protein was used as a binding solution, the significantly higher fluorescence,
indicating higher binding, means that the experiment works successfully and liposomes with the
drug are capable of targeted drug delivery at the ACE2 receptors.

Lentiviral transfection of A549 cells
First the optimal dose of antibiotic (Hygromycin) was determined. This is the
concentration of Hygromycin that kills all of the A549 cells (lung carcinoma cells from human
alveolar basal epithelium). The lentivirus, hACE2 Hygtro was rapidly thawed from -80°C and
was diluted to prepare a final 1:5 concentration in DMEM media. In a 6-well plate, a control
with no lentivirus and the 1:5 dilution of the lentivirus were plated first. The healthy A549 cells
(50,000 per well) were then plated on top for reverse transduction. The cells were incubated with
the virus for 72 hours. Media was changed and incubated again for another 72 hours. Images of
the cells were taken at this point (Figure 11 b, c). Since the cells were over 70% confluent, they
were trypsinized and moved to a T-25 flask. Hygromycin (600ug/ml) was added to the media in
both the flasks. The plate was observed every day and regular fluid changes were performed, and
cell growth was monitored. The cells in the first flask, without any lentivirus are expected to all
die and the cells that have been successfully transfected, should survive since the virus provides
antibiotic resistance. After this is completed, the ACE2 expression on the transfected cells will
be measured using Flow cytometry.
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Figure 11: 6-well plate arrangement for lentiviral transfection.
Fig 11a shows the 6-well plate arrangement where well A1 has A549 cells with no lentivirus and
well B3 has the 1:5 dilution of lentivirus with the A549 cells. Fig 11b is an image captured of the
A549 cells without lentivirus post transfection, before being selected using Hygromycin. Fig 11b
is the image captured of the A549 cells that have been transfected with the lentivirus before
adding Hygromycin. At this point the cells in the well were over 70% confluent and were moved
to a T-25 flask.
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Chapter 7: Conclusion
COVID-19 has become a top priority among researchers across the globe with the race
for the vaccine and drugs being the forefront of research efforts. In vitro studies show that
Remdesivir is effective as a treatment for COVID-19. However, the low efficacy in patients and
the risk of side effects that could be fatal, along with the limited data available on it has
prevented it from being approved by the FDA. Enveloping the drug in the hydrophobic layer of
the liposomes was done successfully. These liposomes had anti-ACE2 antibodies on the outside
which could bind specifically to the ACE2 receptors. This design would allow the drug to be
encapsulated in the liposome that specifically targets the same ACE2 receptors as the SARSCov-2 virus. Thus, the drug delivery will be localized improving the efficacy of the treatment of
COVID-19. Since the highest dose of this antiviral will be where the virus is located, it would
reduce the side effects in the kidneys and liver and reduce mortality making this an appealing
treatment option for patients suffering from COVID-19.
While this is the first step in potentially improving patient outcomes by addressing
existing concerns with the use of Remdesivir this targeted delivery system needs to be tested in
vitro and in animal models. The first step would be to measure the uptake and binding of the
drug in the treatment of human epithelial cells (A549) that have been transfected with the
lentivirus in order to express ACE2 receptors. The targeted liposomes are expected to bind to the
ACE2 receptors that the cells are expressing.
In order to test the efficacy of these liposomes in vivo in small animals, the ideal animals
are hamsters according to a study published by Imai et al4. According to another publication by
Sia et al, indicated that “the features associated with SARS-CoV-2 infection in golden hamsters
resemble those found in humans with mild SARS-CoV-2 infections”37. Thus, testing the efficacy
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of Remdesivir encapsulated in targeted liposomes in COVID-19 infected hamsters would be a
good way to understand the therapeutic effect of the drug in vivo before testing in patients.
While the vaccine has an important role in the prevention of COVID-19 infection, this treatment
will help alleviate the symptoms of thousands of patients worldwide that are suffering from the
disease.
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